Video

Deciding Best Next Steps in Prostate Cancer Treatment

Author(s):

Matthew R. Cooperberg, M.D., M.P.H.

Here's how one expert decides on the next steps in treatment when a man with prostate cancer has a rising PSA and no visible metastases.

There is no standard protocol for treating men with prostate cancer who are on hormonal therapy and have a rising PSA, but no signs of metastasis.

When deciding on the next line of treatment, Matthew R. Cooperberg, M.D., M.P.H., associate professor and Epidemiology & Biostatistics Helen Diller Family Chair in Urology at UCSF, said that he looks at the details: What is the patient's Gleason score, prior treatments and other aggressive characteristics of the disease?

This group of patients will likely require more systemic treatment with novel agents. Patients and physicians should discuss risks, treatment side effects and the cancer's aggressiveness when deciding when it is the right time to start, says Cooperberg.

Related Videos
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.
Dr. Anna Arthur is the Director of the Medical Nutrition Science Program, as well as a tenure-track Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center.
Dr. Ritu Salani, the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA), UCLA Health, and a board-certified gynecologic oncologist.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Michael Bogenschutz
Related Content
Image of man with black hair.
February 3rd 2025

Rybrevant Alone and in Combo With Chemo is Efficacious in HER+ mCRC

Ryan Scott
Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Image of man holding his stomach.
January 24th 2025

Second Cancer Risk Heightened After Appendiceal Adenocarcinoma Diagnosis

Spencer Feldman
Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including colorectal and prostate cancers.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of man with grey hair.
January 16th 2025

An Expert Breaks Down the Meaning of MRD Testing in Cancer Care

Ryan Scott
Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients with various types of cancer.
Image of food.
January 16th 2025

Diet Plus Fish Oil May Reduce Ki-67 Biomarkers in Prostate Cancer

Spencer Feldman
A diet high in omega-3 fatty acids and low in omega-6 fatty acids, taken with fish oil, reduced the Ki-67 index in men with prostate cancer on active surveillance.